Aurobindo Pharma Future Growth

Future criteria checks 1/6

Aurobindo Pharma is forecast to grow earnings and revenue by 13.9% and 8.4% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 12.8% in 3 years.

Key information

13.9%

Earnings growth rate

13.7%

EPS growth rate

Pharmaceuticals earnings growth	18.3%
Revenue growth rate	8.4%
Future return on equity	12.8%
Analyst coverage	Good
Last updated	13 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BSE:524804 - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	371,099	49,285	42,798	59,262	24
3/31/2026	347,698	45,818	35,215	53,142	27
3/31/2025	314,603	37,211	29,903	45,853	27
9/30/2024	302,950	35,816	-7,760	15,867	N/A
6/30/2024	297,184	35,214	N/A	N/A	N/A
3/31/2024	290,019	31,730	-11,270	24,345	N/A
12/31/2023	278,947	27,705	N/A	N/A	N/A
9/30/2023	269,500	23,254	-16,080	19,946	N/A
6/30/2023	254,700	19,777	N/A	N/A	N/A
3/31/2023	248,554	19,275	-3,336	23,868	N/A
12/31/2022	241,918	19,977	N/A	N/A	N/A
9/30/2022	237,869	21,112	28,497	52,208	N/A
6/30/2022	239,894	23,987	N/A	N/A	N/A
3/31/2022	234,555	26,482	23,118	50,165	N/A
12/31/2021	236,476	28,676	N/A	N/A	N/A
9/30/2021	240,103	52,109	1,278	28,769	N/A
6/30/2021	245,518	53,217	N/A	N/A	N/A
3/31/2021	247,746	53,348	14,552	33,291	N/A
12/31/2020	249,316	53,831	N/A	N/A	N/A
9/30/2020	244,617	31,421	29,266	42,542	N/A
6/30/2020	235,787	29,757	N/A	N/A	N/A
3/31/2020	230,985	28,451	29,502	43,813	N/A
12/31/2019	222,323	25,666	N/A	N/A	N/A
9/30/2019	216,070	25,733	N/A	N/A	N/A
6/30/2019	207,579	25,449	N/A	N/A	N/A
3/31/2019	195,636	23,647	919	16,510	N/A
12/31/2018	183,834	23,078	N/A	N/A	N/A
9/30/2018	174,246	21,906	N/A	N/A	N/A
6/30/2018	171,091	23,603	N/A	N/A	N/A
3/31/2018	164,630	24,232	N/A	19,545	N/A
12/31/2017	159,381	24,271	N/A	N/A	N/A
9/30/2017	154,903	24,107	N/A	N/A	N/A
6/30/2017	148,279	22,352	N/A	N/A	N/A
3/31/2017	149,334	23,017	N/A	32,786	N/A
12/31/2016	151,565	22,809	N/A	N/A	N/A
9/30/2016	147,559	22,466	N/A	N/A	N/A
6/30/2016	143,446	20,945	N/A	N/A	N/A
3/31/2016	138,162	20,251	N/A	14,198	N/A
12/31/2015	133,249	18,230	N/A	N/A	N/A
9/30/2015	129,956	16,724	N/A	N/A	N/A
6/30/2015	125,433	15,928	N/A	N/A	N/A
3/31/2015	121,340	15,758	N/A	12,368	N/A
12/31/2014	112,825	16,738	N/A	N/A	N/A
9/30/2014	102,756	17,069	N/A	N/A	N/A
6/30/2014	93,109	15,697	N/A	N/A	N/A
3/31/2014	81,002	11,729	N/A	6,463	N/A
12/31/2013	73,736	7,797	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524804's forecast earnings growth (13.9% per year) is above the savings rate (6.7%).

Earnings vs Market: 524804's earnings (13.9% per year) are forecast to grow slower than the Indian market (17.9% per year).

High Growth Earnings: 524804's earnings are forecast to grow, but not significantly.

Revenue vs Market: 524804's revenue (8.4% per year) is forecast to grow slower than the Indian market (10.5% per year).

High Growth Revenue: 524804's revenue (8.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 524804's Return on Equity is forecast to be low in 3 years time (12.8%).

Aurobindo Pharma Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased by 9.8% to ₹1,474

Price target increased by 7.9% to ₹1,292

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Price target increased by 7.2% to ₹1,071

Price target increased by 10% to ₹959

Recent updates

Second quarter 2025 earnings released: EPS: ₹14.00 (vs ₹12.83 in 2Q 2024)

Aurobindo Pharma Limited to Report Q2, 2025 Results on Nov 09, 2024

Aurobindo Pharma Limited Receives USFDA Approval for Cephalexin Tablets USP, 250 Mg and 500 Mg

Aurobindo Pharma Limited (NSEI:AUROPHARMA) entered into a binding agreement to acquire remaining 49% stake in Gls Pharma Limited from Suresh Pathak and his family members for approximately INR 225 million.

Eugia Steriles Private Limited Receives Its First Product Approval by the United States Food and Drug Administration

Aurobindo Pharma Limited Approves Interim Dividend for the Financial Year 2023-24

Price target increased by 9.8% to ₹1,474

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited (NSEI:AUROPHARMA) announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.

Now 20% overvalued after recent price rise

Price target increased by 7.9% to ₹1,292

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹959

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 15% to ₹775

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Price target decreased to ₹621

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.

First quarter 2023 earnings released: EPS: ₹8.88 (vs ₹13.14 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. Announces Settlement with Aurobindo to Resolve AUSTEDO® (deutetrabenazine) Patent Dispute

Price target decreased to ₹734

Aurobindo Pharma Limited Announces Fourth Interim Dividend for the Financial Year 2021-22, Payable on or Before June 15, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Less than half of directors are independent

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Domestic formulation business of Veritaz Healthcare from Veritaz Healthcare Limited for INR 1710 million.

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Business and certain assets of Veritaz Healthcare Limited for 1710 million.

Blackstone Reportedly Closing in on Aurobindo's Injectables Business